Deoxynucleoside Therapy for Restoring Mitochondrial Nucleotide Pools
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective therapeutic interventions for mitochondrial DNA depletion syndromes, particularly thymidine kinase 2 (TK2) deficiency, as current treatments are limited to supportive therapies and there is an underdiagnosis of this disorder.
Innovation Solution
Administering deoxynucleosides such as deoxythymidine (dT) and deoxycytidine (dC) to restore balanced nucleotide pools, which are essential for mitochondrial DNA synthesis, through oral, intrathecal, or intravenous routes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If deoxynucleosides are administered to treat TK2 deficiency, then clinical symptoms improve and lifespan extends, but the complexity of therapeutic intervention increases
Solution Approach 1:
The patent applies parameter changes by administering specific deoxynucleosides (deoxythymidine and deoxycytidine) at controlled dosages to restore balanced nucleotide pools in TK2-deficient patients. This chemical parameter modification directly addresses the metabolic deficiency without requiring complex surgical or mechanical interventions, thereby improving therapeutic efficacy while maintaining relatively simple treatment protocols
2Object-affected harmful factors
If supportive therapies are used for mitochondrial diseases, then patient safety is maintained, but therapeutic effectiveness is limited
Solution Approach 1:
The patent introduces deoxynucleosides as intermediary substances that mediate between the deficient TK2 enzyme function and the required nucleotide pool balance. These intermediaries serve as substrates that can be phosphorylated by the residual TK2 activity to produce deoxynucleotides, thereby bridging the metabolic gap more effectively than general supportive therapies while maintaining patient safety through controlled administration
Data Source
AI summary
The invention relates generally to a pharmacological therapy for human genetic diseases, specifically those characterized by unbalance nucleotide pools, more specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxynucleoside, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine (dT) or deoxycytidine (dC), or mixtures thereof. This administration of deoxynucleosides is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.